Levetiracetam (Epilepsy)

Oro-facial clefts

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7651
R22633		 Tomson (Levetiracetam), 2018 Cleft lip or palate at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 1.40 [0.15;13.48] C 1/599   3/2,514 4 599
ref
S5938
R23790		 Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 Oral clefts 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No Controls: mixed indications 0.23 [0.01;4.04] C 0/450   7/1,562 7 450
ref
S6063
R15767		 Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006 Facial cleft 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 10.01 [0.40;252.84] C 0/22   1/647 1 22
ref
Total 3 studies 1.34 [0.20;9.12] 12 1,071
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Tomson (Levetiracetam), 2018Tomson, 2018 1 1.40[0.15; 13.48]459942%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012Hernández-Díaz, 2012 2 0.23[0.01; 4.04]745031%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 3 10.01[0.40; 252.84]12226%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 32% 1.34[0.20; 9.12]121,0710.250.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam; 2: Levetiracetam) (Controls exposed to Lamotrigine, sick; 3: Levetiracetam) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.34[0.20; 9.12]121,07132%NATomson (Levetiracetam), 2018 Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006 3 case control studiescase control studies 0 Type of controls exposed to other treatment, sickexposed to other treatment, sick 1.34[0.20; 9.12]121,07132%NATomson (Levetiracetam), 2018 Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006 3 Tags Adjustment   - No  - No 1.34[0.20; 9.12]121,07132%NATomson (Levetiracetam), 2018 Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006 3 Controls   - mixed indications  - mixed indications 0.23[0.01; 4.04]7450 -NAHernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 1 All studiesAll studies 1.34[0.20; 9.12]121,07132%NATomson (Levetiracetam), 2018 Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006 30.150.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.34[0.20; 9.12]121,07132%NATomson (Levetiracetam), 2018 Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006 30.510.01.0